Broad-spectrum crispr-mediated inhibition of sars-cov-2 variants and endemic coronaviruses in vitro

HIGHLIGHTS

• who: Leiping Zeng from the Stanford University, Stanford, CA, USA have published the research work: Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
• what: The authors demonstrate that Cas13d effectively targets and inhibits diverse strains of coronaviruses both as a prophylactic and a treatment, including SARS-CoV-2 and other coronaviruses. The authors provide substantial evidence that CRISPR-Cas13d can work efficiently as a BSA agent against diverse SARS-CoV-2_variants, including Omicron, as well as endemic human respiratory coronavirus strains . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.